Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
42
Not yet recruiting, industry sponsors, Infectious disease and vaccines, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,780
42 trials
Showing 1 to 25, recently updated first.
Triastek, lnc.Industry
NCT07951138 · 18 participants (planned) · Start Nov 16, 2026 · Primary completion Dec 19, 2026
Drug: Itraconazole Tablet(T26); Sporanox® · For: Fungal Infections
Sites: Chongqing, China
- Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis BNot yet recruiting
Xiamen Amoytop Biotech Co., Ltd.Industry
NCT07946757 · 60 participants (planned) · Start Dec 31, 2026 · Primary completion Feb 2027
Drug: ACT201 Injection; PegIFNα-2b Injection and 2 more · For: Chronic Hepaititis B
Sites: Beijing, China; Xi'an, China; Xiamen, China
- An Evaluation of the Potential for VH4011499 Drug-drug-interactionsNot yet recruiting
ViiV HealthcareGSK (GSK)
NCT07939594 · 75 participants (planned) · Start Nov 16, 2026 · Primary completion Mar 12, 2027
Drug: VH4011499; Ritonavir and 6 more · For: HIV Infections
- Mass Balance and Absolute Bioavailability of [14C]-VH4011499Not yet recruiting
ViiV HealthcareGSK (GSK)
NCT07934719 · 18 participants (planned) · Start Nov 9, 2026 · Primary completion Feb 18, 2027
Drug: VH4011499; [14C]-VH4011499 (IV) and 1 more · For: HIV Infections
- ACT201 Injection in Participants With Chronic Hepatitis B (CHB) on Nucleos(t)Ide Analog Therapy - Phase IbNot yet recruiting
Xiamen Amoytop Biotech Co., Ltd.Industry
NCT07929805 · 40 participants (planned) · Start Nov 20, 2026 · Primary completion Feb 2027
Drug: ACT201 Injection; ACT201 Injection and 2 more · For: Chronic Hepaititis B
Sites: Beijing, China; Wuhan, China; Xi'an, China · 4 sites in all
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07925775 · 96 participants (planned) · Start Oct 31, 2026 · Primary completion Mar 31, 2027
Drug: Investigational vaccine low dose; Investigational vaccine high dose and 1 more · For: Lower Respiratory Tract Disease Caused by RSV Infection
- Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDSNot yet recruiting
AVM Biotechnology IncIndustry
NCT04366115 · 16 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 1, 2031
Drug: AVM0703; Placebo · For: ARDS; Covid19; Influenza, Human
- A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult ParticipantsNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07905157 · 98 participants (planned) · Start Nov 3, 2026 · Primary completion Mar 30, 2027
Drug: Bepirovirsen · For: Hepatitis B
- Phase Ia/Ib Trial of SCTA02A Injection in Healthy Adults and Patients With Chronic Hepatitis BNot yet recruiting
Sinocelltech Ltd.Industry
NCT07903831 · 60 participants (planned) · Start Oct 2026 · Primary completion Sep 2027
Drug: SCTA02A; Placebo · For: Hepatitis B
Sites: Beijing, China
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)Pivotal-lookingNot yet recruiting
Grand Theravac Life Sciences (Hangzhou) Co., Ltd.Industry
NCT07897448 · 105 participants (planned) · Start Oct 31, 2026 · Primary completion Sep 22, 2028
Drug: AHB-137; TVAX-008 and 2 more · For: Chronic Hepatitis B
- A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid TumorsNot yet recruiting
Medsyn Biopharma, LLCIndustry
NCT07899632 · 75 participants (planned) · Start Nov 2026 · Primary completion Aug 2029
Drug: MDSY-1240 · For: Triple-Negative Breast Cancer (TNBC); Gastric Cancer (GC); Gastric Cancer Adenocarcinoma Metastatic and 11 more
- Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)Pivotal-lookingNot yet recruiting
Sinovac Biotech Co., LtdIndustry
NCT07889193 · 175 participants (planned) · Start Oct 2026 · Primary completion Dec 2026
Drug: Cell-based Trivalent Split Influenza Virus Vaccine (cTIV); Egg-based Trivalent Split Influenza Virus Vaccine (eTIV) · For: Seasonal Influenza
Sites: Guangzhou, China
- A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) ParticipantsPivotal-lookingNot yet recruiting
Ausper Biopharma Co., Ltd.Industry
NCT07884864 · 110 participants (planned) · Start Oct 28, 2026 · Primary completion Apr 30, 2027
Drug: AHB-121; Placebo · For: Chronic Hepatitis B Virus
Sites: Shanghai, China
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)Pivotal-lookingNot yet recruiting
Ausper Biopharma Co., Ltd.Industry
NCT07876856 · 105 participants (planned) · Start Oct 31, 2026 · Primary completion Sep 22, 2028
Drug: AHB-137; Placebo and 1 more · For: Chronic Hepatitis B
- A Trial of RLX-2508-102 in Healthy VolunteersPivotal-lookingNot yet recruiting
Atridia Pty Ltd.Industry
NCT07873671 · 101 participants (planned) · Start Nov 15, 2026 · Primary completion Jan 30, 2029
Drug: RLX-2508; RLX-2508 and 2 more · For: Influenza
Sites: Sydney, Australia; Brisbane, Australia; Melbourne, Australia
- A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis AntibioticsNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07371429 · 25 participants (planned) · Start Sep 18, 2026 · Primary completion Aug 23, 2027
Drug: Gepotidacin; SOC · For: Urinary Tract Infections
Sites: Orange, California; Shreveport, Louisiana; Baltimore, Maryland · 4 sites in all
- A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIVPivotal-lookingNot yet recruiting
ViiV HealthcareGSK (GSK)
NCT07822477 · 160 participants (planned) · Start Nov 6, 2026 · Primary completion May 9, 2029
Drug: VH5356136 Formulation 1; VH5356136 Formulation 2 and 2 more · For: HIV Infections
Xiamen Amoytop Biotech Co., Ltd.Industry
NCT07589400 · 24 participants (planned) · Start Oct 30, 2026 · Primary completion Mar 30, 2027
Drug: ACT500 Tablets; ACT500 Tablets and 4 more · For: Metabolic Dysfunction-associated Steatotic Liver Disease; Chronic Hepatitis b
Sites: Beijing, China; Shanghai, China; Ürümqi, China · 4 sites in all
- Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and OlderPivotal-lookingNot yet recruiting
Yikang Biotech (Suzhou) Co., Ltd.Industry
NCT07807449 · 128 participants (planned) · Start Sep 15, 2026 · Primary completion Jan 22, 2027
Drug: Recombinant RSV Vaccine (CHO Cell); Recombinant RSV Vaccine (CHO Cell) and 3 more · For: Respiratory Syncytial Virus (RSV)
Sites: Yixing, China
- Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 YearsNot yet recruiting
BMI KoreaIndustry
NCT07791186 · 72 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 31, 2027
Drug: BMI2012 low-dose; BMI2012 mid-dose and 1 more · For: Prevention of COVID-19 Variant (Omicron JN.1)
Sites: Seoul, South Korea; Suwon, South Korea · 3 sites in all
- A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)Not yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07600775 · 14 participants (planned) · Start Sep 1, 2026 · Primary completion Jan 19, 2027
Drug: MK-8527; Rifampin · For: Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis
SecuraBioIndustry
NCT07714187 · 30 participants (planned) · Start Jan 2027 · Primary completion Oct 2028
Drug: Duvelisib · For: Mycosis Fungoides; Cutaneous T-cell Lymphoma
Sites: Baltimore, Maryland
GlaxoSmithKlineGSK (GSK)
NCT07406347 · 60 participants (planned) · Start Jan 25, 2027 · Primary completion Oct 18, 2028
Drug: Pn-MAPS30plus · For: Pneumonia, Bacterial
- Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TVAX-028 in the Treatment of Chronic Hepatitis BNot yet recruiting
Grand Theravac Life Sciences (Nanjing) Co., Ltd.Industry
NCT07673068 · 32 participants (planned) · Start May 31, 2026 · Primary completion May 31, 2027
Drug: TVAX-028 · For: HBV Infection
- Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 SymptomsNot yet recruiting
Kimera Labs Inc.Industry
NCT07664696 · 64 participants (planned) · Start Jan 2027 · Primary completion Jun 2028
Drug: IV infusion using an isolated, placental, mesenchymal stem cell derived EVs; Placebo IV administration · For: COVID-19
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.